Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting

Fig. 1

HSPD1 is a fitness gene with prognostic power ubiquitously expressed in NSCLC tumors and cells. A) Fitness score for HSPD1 in lung adenocarcinoma (ADC) and squamous cell carcinoma (SqCC). Each dot represents a single gene. B) RSA (redundant siRNA activity) waterfall plot of HSPD1 sensitivity score from PROJECTDRIVE showing HSPD1 as an essential gene in non-small cell lung cancer (NSCLC) cell lines (n = 52). RSA sensitivity score < -3. C) Overall survival analysis between the low- and high-HSPD1 groups in TCGA LUAD (N = 510) and GSE30219 (N = 293). P-value was calculated using log-rank test. Time is expressed as months. Relapse-free (D) and disease-specific (E) survival analysis between low- and high-HSPD1 groups in GSE30219 (N = 293) and TCGA LUAD (N = 510), respectively. P-value was calculated using log-rank test. Time is expressed as months. IHC staining of HSPD1 in cancer tissues (F, G, H and I) derived from 30 lung cancer patients (peritumoral bronchial structure in upper right corner of panel F). J) Pie chart of HSPD1 predominant intensity in NSCLC patient-derived samples. K) Western blot quantification of HSPD1 in a panel of different human (A549, Calu-1, SK-MES-1, H460, H520, H1299 and H23) and mouse (Ladi3.1, LL2 and Ladi2.1) NSCLC cells. β-Actin was used as loading control. HSPD1 quantification was normalized to β-Actin. L) Western blot analysis of HSPD1 in cytosolic (named as C) or mitochondrial (named as M) fraction. β-Actin was used as loading control and TOMM20 was used as control for cytosolic/mitochondrial fractionation

Back to article page